Reduced folate receptor alpha (FOLR1) protein expression in fallopian tubes from premenopausal women: implications for the FOLR1 CDx assay for mirvetuximab‐soravtansine therapy

Abstract Mirvetuximab‐soravtansine (MIRV‐S) is an antibody‐drug conjugate targeting folate receptor alpha (FOLR1). MIRV‐S is approved for the treatment of FOLR1‐positive, platinum‐resistant ovarian carcinoma. Patient eligibility is determined by immunohistochemistry (IHC) using a companion diagnosti...

Description complète

Détails bibliographiques

Auteurs principaux:	Annika Nasdala, Leonie D Kandt, Martin Radner, Nora Schaumann, Malte Gronewold, Pia Hillmann, Henriette Christgen, Jens Hachenberg, Elna Kuehnle, Christian Hartmann, Matthias Christgen
Format:	Artigo
Langue:	Inglês
Publié:	Wiley 2026-05-01
Collection:	The Journal of Pathology: Clinical Research
Sujets:	ovarian carcinoma standardized controls reference materials immunohistochemistry folate receptor alpha (FOLR1)
Accès en ligne:	https://doi.org/10.1002/2056-4538.70091
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!